Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ELIZABETH SHPALL and SIMRIT PARMAR.
ELIZABETH SHPALL
Connection Strength
4.225
SIMRIT PARMAR
  1. Treg adoptive therapy: is more better? Blood. 2016 Feb 25; 127(8):962-3.
    View in: PubMed
    Score: 0.568
  2. Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo. Blood. 2015 Feb 26; 125(9):1502-6.
    View in: PubMed
    Score: 0.521
  3. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy. 2014 Jan; 16(1):90-100.
    View in: PubMed
    Score: 0.484
  4. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017 05; 177(3):457-466.
    View in: PubMed
    Score: 0.153
  5. Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials. Front Med (Lausanne). 2015; 2:89.
    View in: PubMed
    Score: 0.140
  6. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92.
    View in: PubMed
    Score: 0.133
  7. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1284-90.
    View in: PubMed
    Score: 0.132
  8. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One. 2013; 8(10):e76781.
    View in: PubMed
    Score: 0.121
  9. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012 Dec 13; 367(24):2305-15.
    View in: PubMed
    Score: 0.114
  10. Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. Cancer Res. 2011 Jul 15; 71(14):5040-9.
    View in: PubMed
    Score: 0.102
  11. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol. 2011 Jan 20; 29(3):294-302.
    View in: PubMed
    Score: 0.099
  12. Umbilical cord blood transplantation. Clin Adv Hematol Oncol. 2010 Nov; 8(11):786-801.
    View in: PubMed
    Score: 0.098
  13. Overcoming the barriers to umbilical cord blood transplantation. Cytotherapy. 2010 Apr; 12(2):121-30.
    View in: PubMed
    Score: 0.094
  14. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood. 2009 Oct 01; 114(14):2884-7.
    View in: PubMed
    Score: 0.090
  15. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan???clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant. 2022 08; 57(8):1295-1303.
    View in: PubMed
    Score: 0.055
  16. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica. 2022 04 01; 107(4):899-908.
    View in: PubMed
    Score: 0.054
  17. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021 07 27; 5(14):2799-2806.
    View in: PubMed
    Score: 0.052
  18. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021 06 10; 137(23):3272-3276.
    View in: PubMed
    Score: 0.051
  19. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther. 2021 05; 27(5):430.e1-430.e7.
    View in: PubMed
    Score: 0.050
  20. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther. 2021 03; 27(3):243.e1-243.e6.
    View in: PubMed
    Score: 0.050
  21. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020 08 25; 4(16):3943-3951.
    View in: PubMed
    Score: 0.049
  22. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2021; 144(1):74-81.
    View in: PubMed
    Score: 0.048
  23. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019 07; 25(7):1340-1346.
    View in: PubMed
    Score: 0.044
  24. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant. 2019 05; 25(5):1039-1044.
    View in: PubMed
    Score: 0.043
  25. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol. 2018 Nov; 5(11):e532-e542.
    View in: PubMed
    Score: 0.043
  26. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. Eur J Haematol. 2017 Dec; 99(6):532-535.
    View in: PubMed
    Score: 0.040
  27. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2018 06; 24(6):1232-1236.
    View in: PubMed
    Score: 0.040
  28. Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget. 2017 Jun 20; 8(25):41620-41630.
    View in: PubMed
    Score: 0.039
  29. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer. 2017 Sep 15; 123(18):3568-3575.
    View in: PubMed
    Score: 0.039
  30. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biol Blood Marrow Transplant. 2017 Aug; 23(8):1359-1366.
    View in: PubMed
    Score: 0.039
  31. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood. 2017 06 01; 129(22):3031-3033.
    View in: PubMed
    Score: 0.038
  32. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol. 2017 05; 177(4):567-577.
    View in: PubMed
    Score: 0.038
  33. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. 2016 Dec 15; 122(24):3831-3837.
    View in: PubMed
    Score: 0.037
  34. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 2016 07 14; 128(2):297-312.
    View in: PubMed
    Score: 0.036
  35. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant. 2016 May; 22(5):961-5.
    View in: PubMed
    Score: 0.036
  36. Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China. Leuk Lymphoma. 2016 07; 57(7):1534-8.
    View in: PubMed
    Score: 0.035
  37. Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leuk Lymphoma. 2016 07; 57(7):1607-15.
    View in: PubMed
    Score: 0.035
  38. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica. 2015 Oct; 100(10):1361-70.
    View in: PubMed
    Score: 0.034
  39. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplant. 2015 Jul; 50(7):939-946.
    View in: PubMed
    Score: 0.033
  40. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 2014 Sep 25; 124(13):2034-45.
    View in: PubMed
    Score: 0.032
  41. Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. Leuk Lymphoma. 2015 Feb; 56(2):533-5.
    View in: PubMed
    Score: 0.032
  42. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy. 2014 Jan; 16(1):84-9.
    View in: PubMed
    Score: 0.030
  43. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1453-8.
    View in: PubMed
    Score: 0.030
  44. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1227-32.
    View in: PubMed
    Score: 0.029
  45. Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC. PLoS One. 2012; 7(12):e51390.
    View in: PubMed
    Score: 0.028
  46. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant. 2013 Mar; 19(3):410-7.
    View in: PubMed
    Score: 0.028
  47. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1835-44.
    View in: PubMed
    Score: 0.028
  48. Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1819-26.
    View in: PubMed
    Score: 0.028
  49. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1677-86.
    View in: PubMed
    Score: 0.027
  50. HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiological immune surveillance. Leukemia. 2011 Jun; 25(6):1036-9.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.